Network-based approaches open a new avenue to classify and treat rare diseases

Gene Mutation in the Immune System: Anti-Diabetes Drugs Make Immune Cells More Effective Again

“I think there are few things that so many people agree on as that it is good to support St. Anna CCRI!”

Kaan Boztug explains defect in DOCK 11

Childhood cancer: “New” immune system responds better to therapy

(Vienna, 9.8.2023) Scientists at St. Anna Children's Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children. Crucially, stem cells from a parent provide children with a new immune system that responds much better to immunotherapies. These results of an early clinical trial were published in the prestigious Journal of Clinical Oncology.

St. Anna CCRI welcomes George Cresswell as new Principal Investigator

Sarcoma Awareness Month: exposing an insidious Nemesis

“I wish you the best of luck and groundbreaking research results!”

Automated testing of pediatric cancer therapies

With a novel High-Throughput-Screening method the efficacy of numerous drugs can be tested simultaneously. Researchers are now able to quickly and efficiently assess which substances are effective against certain tumors. A team led by Martin Distel, PhD, and Sabine Taschner-Mandl, PhD, of St. Anna Children's Cancer Research Institute has now provided the first guide on how to use this method to test the sensitivity of childhood tumors to different drugs in zebrafish models. The study was published in the Journal npj Precision Oncology.

Childhood cancer: Vulnerability in the immune response against metastases discovered

Scientists led by Sabine Taschner-Mandl, PhD, St. Anna Children's Cancer Research Institute, and Nikolaus Fortelny, PhD, Paris Lodron University of Salzburg, are the first to analyze bone marrow metastases from childhood tumors of the nervous system using modern single-cell sequencing analysis. It turns out that cancer cells prevent cells in their environment from fighting the tumor – a process that could be reversed with medication. The findings were published in the renowned journal Nature Communications.

Newly discovered genetic defect disrupts blood formation and immune system

The first-ever ITCC Scientific Days concluded with big success! 

Florian Grebien appointed as new Principal Investigator at St. Anna CCRI

Prof. Florian Grebien, PhD, is eager to understand why some childhood leukemias show poor treatment response and how this can be tackled. To this end, he is now establishing his own team at St. Anna Children's Cancer Research Institute (St. Anna CCRI). "Prof. Grebien is an outstanding researcher. We have followed his scientific achievements for many years and are very pleased to have been able to recruit him as a Principal Investigator to St. Anna CCRI," says Prof. Kaan Boztug, MD, Scientific Director of St. Anna CCRI.

EuSARC 2023 in Vienna: Bringing together sarcoma researchers from across the world

Innovative Therapies for Children with Cancer: ITCC Conference for the first time in Vienna

International sarcoma meeting “EuSARC” hosted by St. Anna CCRI in Vienna

From May 18th to 20th, St. Anna Children’s Cancer Research Institute (St. Anna CCRI) welcomes scientists and physicians from Europe, the USA, and beyond, at the EuSARC 2023 meeting in Vienna. EuSARC is a Europe-wide group of scientists holding annual meetings to address the dire need for novel therapies in sarcomas, a group of poorly explored bone and soft tissue tumors.